Headed up by an experienced team with close ties to Johns Hopkins and, as a spin-off from Theraly Pharmaceuticals, Theraly Fibrosis was set up to lead commercialization efforts for new therapies for the treatment of chronic rare fibrotic diseases by focusing on efficiently generating medically important, stable, and long-acting therapies. Theraly enables products using its proprietary platform technology (4G-PEG) that can empower short-acting peptides and proteins by dramatically increasing their half-lives while maintaining potency. The firm's lead program: TLY012, (a recombinant human protein) is a preclinical stage product in development for organ fibrosis. TLY012, has shown therapeutic efficacy in a number of pre-clinical models of organ fibrosis, autoimmune/inflammatory conditions, and in oncology. In diabetes, Theraly's lead product Olaedin® is a long-acting form of exenatide that utilizes the firm's 4G-PEG technology. Olaedin can be administered as a once-weekly or once-monthly s.c dose without using recombinant technology or depot systems. Theraly has enabled multiple additional products using its 4G-PEG technology.
